Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠Persistent Cash Burn ⢠Equity Dilution Risk PHVS has ample cash and minimal debt, but its lack of revenue, persistent losses, negative cash flow, dilution risk, and premium valuation make it a high-risk investment pending clinical or commercial progress.
Price Behavior
Key Price Behavior Insights: ⢠Short-term uptrend ⢠Resistance test ⢠Pullback risk Support Level: $37.00â$37.30 Resistance Level: $37.80â$38.00 PHVS is in a constructive short-term uptrend, but needs to hold $37.00â$37.30 and decisively clear $38.00 to sustain momentum amid pullback risk near recent highs.
Sentiment & News
Key News Insights: ⢠Phase 3 Success ⢠2027 Filing Path ⢠Rising Institutional Interest Pharvaris' positive Phase 3 CHAPTER-3 results for deucrictibant strengthen its path toward 2027 regulatory filings and reinforce bullish clinical momentum.
AI Summary
PHVS is now an approval-and-launch execution story: CHAPTER-3 meaningfully de-risks oral prophylactic deucrictibant, but its premium valuation and ongoing cash burn leave little room for FDA delays, weak payer uptake, or further dilutive financing ahead of the April 2027 on-demand PDUFA.
Description
Pharvaris N.V. is a clinicalâstage biopharmaceutical company developing treatments for rare diseases, with a primary program targeting hereditary angioedema (HAE). Its lead smallâmolecule bradykinin B2âreceptor antagonist is in Phase II, and the pipeline includes both an onâdemand oral soft capsule in Phase II and an extendedârelease prophylactic tablet in early clinical testing. The company operates in the Netherlands, Switzerland and the United States and was founded in 2015 with headquarters in Leiden, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 1 | Apr 8 | PHVS | Pharvaris N.V. | Clear near-term catalyst path (on-demand deucrictibant NDA filing targeted for 1H 2026 and pivotal CHAPTER-3 topline expected 3Q 2026), strong cash (~$329M runway into 1H 2027), bullish analyst targets (~60% implied upside) and ~12.6% 3-week rally with price ~15% above 21-day SMA. This makes it an attractive short-term catalyst/momentum trade despite biotech volatility. | Closed | -6.4% |